Top Page
MedAdvisor Limited
(Sydney:MDR)
MedAdvisor Limited (MDR) vs. S&P 500 (SPY)
MedAdvisor Limited Business Overview & Revenue Model
MedAdvisor Limited Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 122.11M | 97.96M | 67.75M | 38.77M | 9.60M | Gross Profit |
| 23.63M | 12.59M | -1.84M | -6.06M | -3.63M | EBIT |
| 2.70M | -7.72M | -16.19M | -18.31M | -11.13M | EBITDA |
| 7.05M | -3.03M | -11.29M | -14.93M | -10.34M | Net Income Common Stockholders |
| 792.13K | -11.31M | -17.35M | -13.95M | -9.58M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 15.58M | 14.20M | 7.58M | 7.15M | 12.35M | Total Assets |
| 98.78M | 95.91M | 78.44M | 80.92M | 21.27M | Total Debt |
| 12.61M | 13.09M | 13.41M | 9.16M | 1.42M | Net Debt |
| -2.97M | -1.11M | 5.84M | 2.01M | -10.92M | Total Liabilities |
| 47.20M | 47.45M | 43.89M | 32.07M | 4.25M | Stockholders Equity |
| 51.58M | 48.46M | 34.55M | 48.45M | 16.66M |
| Cash Flow | Free Cash Flow | |||
| 3.35M | -1.63M | -548.13K | -12.94M | -9.00M | Operating Cash Flow |
| 5.19M | -1.45M | -236.32K | -12.54M | -8.68M | Investing Cash Flow |
| -2.80M | -3.23M | -290.79K | -43.36M | 230.68K | Financing Cash Flow |
| -831.97K | 12.42M | 1.86M | 50.72M | 16.39M |
MedAdvisor Limited Technical Analysis
MedAdvisor Limited Peers Comparison
MedAdvisor Limited Corporate Events
MedAdvisor Limited has requested a trading halt on its securities as it prepares to release an announcement regarding a strategic update. This halt is related to a non-binding proposal to acquire its ANZ business division, indicating potential significant changes in its operational focus and market strategy.
MedAdvisor Limited has received a non-binding Letter of Intent from a multinational software company to acquire its ANZ business division, which the directors believe offers a materially higher value than the current share price. This proposal aligns with MedAdvisor’s strategic review process aimed at bridging the valuation gap of its ANZ and US business units. The ANZ division recently achieved record revenue, and the potential acquirer plans to continue investing in the business, benefiting pharmacies across Australia. The transaction, subject to due diligence, is expected to be finalized within 5 to 7 weeks.
MedAdvisor Limited, listed on the Australian Securities Exchange (ASX) under the ticker MDR, has announced the lifting of its trading suspension. This follows the release of an announcement concerning the outcome of a Court application under section 1322 of the Corporations Act 2001, which allows the company to resume trading immediately.
MedAdvisor Limited has announced that the Federal Court of Australia granted their request to rectify an administrative oversight related to a late lodgement of a cleansing notice for shares issued in a recent placement. Following this court order, MedAdvisor has requested the resumption of trading in its securities, which had been voluntarily suspended. This development is expected to restore normal trading operations and maintain investor confidence.
MedAdvisor Limited has released an investor presentation update for the third quarter of FY25, emphasizing that the information provided is for general informational purposes and not intended as financial advice or an investment offer. The presentation includes disclaimers about the accuracy and completeness of the information, highlighting the potential risks and uncertainties associated with forward-looking statements, and advises recipients to conduct their own independent assessments.
MedAdvisor Limited reported a significant decline in its financial performance for 3Q FY25, with operating revenue and gross profit nearly halved compared to the previous year. Despite these challenges, the company is actively pursuing strategic initiatives to capitalize on evolving market trends, including cost optimization and restructuring its US operations. The company also completed a $5 million capital raise to support these initiatives, aiming for sustainable growth in FY26.
MedAdvisor Limited announced that its CEO, Rick Ratliff, and CFO, Ancila Desai, will present the company’s third-quarter FY25 results in a live webinar on April 30, 2025. This event is significant for stakeholders as it provides insights into the company’s operational performance and strategic direction, potentially impacting its market positioning and investor relations.
MedAdvisor Limited has requested a voluntary suspension of its securities from the Australian Securities Exchange (ASX) pending a court application. This action is to ensure that trading does not occur on an uninformed basis while the company seeks to validate a cleansing notice related to share issuance. The suspension will remain until the court’s decision or a further announcement by the company, expected by May 2, 2025.
MedAdvisor Limited has announced an extension to its Share Purchase Plan (SPP) deadline, moving it from April 30, 2025, to May 9, 2025. This extension aims to provide eligible shareholders additional time to participate and complete their applications, potentially impacting shareholder engagement and investment levels.
MedAdvisor Limited has requested a trading halt on its securities pending an important announcement related to a Court order under the Corporations Act. This halt will remain until the announcement is made or until normal trading resumes on April 29, 2025. The decision indicates a significant development that could impact the company’s operations or market positioning, though specific details are yet to be disclosed.
MedAdvisor Limited has announced an extension of its Share Purchase Plan (SPP) deadline from April 17 to April 30, 2025, to provide eligible shareholders additional time to participate. This extension reflects the company’s commitment to engaging its stakeholders and potentially increasing shareholder participation, which may impact its financial strategy and market positioning.
MedAdvisor Limited has reported a change in the substantial holding of Perennial Value Management Limited, which has increased its voting power from 13.33% to 15.03%. This change was facilitated through a series of market transactions involving various financial institutions, indicating an active adjustment in investment strategy. The increase in voting power suggests a stronger influence of Perennial Value Management Limited in MedAdvisor’s corporate decisions, potentially impacting future business strategies and shareholder dynamics.
MedAdvisor Limited has announced a change in the substantial holding of its shares by Jencay Capital Pty Limited. Jencay Capital has increased its voting power from 6.21% to 7.24% through market purchases and participation in a placement, acquiring an additional 8,983,390 shares. This change reflects a strategic move by Jencay Capital to strengthen its influence within MedAdvisor, potentially impacting the company’s governance and future strategic decisions.
MedAdvisor Limited has announced the application for quotation of 45,750,000 fully paid ordinary securities on the Australian Securities Exchange (ASX), set to be issued on April 8, 2025. This move is part of previously announced transactions and is expected to bolster the company’s financial position, potentially enhancing its market presence and offering stakeholders increased investment opportunities.
MedAdvisor Limited has announced the opening of its Share Purchase Plan (SPP) Offer, allowing eligible shareholders to purchase up to $30,000 in fully paid ordinary shares at an issue price of $0.10 per share. This follows a successful placement to institutional investors at the same price, aiming to enhance shareholder value and strengthen the company’s financial position.
MedAdvisor Limited has announced a proposed issue of 20 million ordinary fully paid securities under a securities purchase plan, with the record date set for March 31, 2025, and the offer closing on April 17, 2025. This move is part of MedAdvisor’s strategy to strengthen its financial position, potentially enhancing its market presence and operational capabilities in the digital healthcare sector.
MedAdvisor Limited has announced a capital raising initiative through a placement and a share purchase plan to issue new shares to eligible shareholders. This move is expected to strengthen the company’s financial position, potentially enhancing its market presence and operational capabilities in the healthcare technology sector.
MedAdvisor Limited has successfully completed a $5 million institutional placement and announced a $2 million Share Purchase Plan, aimed at supporting its strategic growth and cost-optimization initiatives. The company is undergoing a strategic review to maximize shareholder value, with strong interest in its Australian business and several non-binding proposals received. The company anticipates revenue growth and margin expansion in the coming years, alongside significant operational cost savings.
MedAdvisor Limited has requested a trading halt on its securities pending an announcement related to a capital raising through a placement and an update on its strategic review. This move is likely to impact the company’s financial strategy and market positioning, signaling potential changes that stakeholders should be aware of.
Jencay Capital Pty Limited has increased its stake in MedAdvisor Limited, raising its voting power from 5.11% to 6.21% by purchasing 6,076,578 ordinary shares. This change in substantial holding reflects Jencay Capital’s growing interest in MedAdvisor, potentially impacting the company’s shareholder dynamics and signaling confidence in its market position.
MedAdvisor Limited has released an investor update for the first half of fiscal year 2025, focusing on reshaping the company for long-term value creation. The presentation emphasizes that the information provided is for general purposes and not intended as financial advice or an offer to sell securities. It highlights the company’s commitment to transparency while disclaiming liability for the accuracy or completeness of the information presented. The update may contain forward-looking statements subject to various risks and uncertainties, urging stakeholders to independently assess the company’s market position and future performance.
MedAdvisor Limited reported a 24.4% decline in group revenue for the first half of FY25, primarily due to reduced vaccine-related health program budgets from key US pharma clients. Despite this, the company achieved a gross margin increase to 61.3% and launched its Transformation 360 initiative, aimed at long-term value creation. The restructuring is expected to yield significant savings, and the company is well-positioned for future growth with a strong US pipeline and steady progress in the ANZ region. The strategic review process to maximize shareholder value is also advancing, with completion anticipated by June 2025.
MedAdvisor Limited reported a significant decline in its financial performance for the half-year ended 31 December 2024, with profits dropping by 79.6% to $1,402,915 and revenues decreasing by 32.3% to $57,106,600. The company did not declare any dividends during this period, reflecting the challenging market conditions and potential impacts on stakeholders.
MedAdvisor Limited has announced an investor webinar for the first half of the fiscal year 2025, to be presented by CEO Rick Ratliff and CFO Ancila Desai. The webinar, scheduled for February 28, 2025, will provide insights into the company’s performance and future plans, potentially impacting its operations and stakeholder interests.